O
XLO icon

OrbiMed’s Xilio Therapeutics XLO Stock Holding History

OrbiMed’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67M Buy
+592,300
New +$4.95M 0.11% 99

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed's XLO Position: Q2 2026 in Review

OrbiMed opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 592,300 shares worth $5.67M. The stake represents 0.11% of the portfolio and ranks #99 among its holdings.

26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • OrbiMed held 592,300 shares of Xilio Therapeutics worth $5.67M as of Q2 2026.
  • Xilio Therapeutics was a new OrbiMed position in Q2 2026.
  • Xilio Therapeutics made up 0.11% of OrbiMed's portfolio in Q2 2026, its #99 holding.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.